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Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder
characterized by symptoms of inattention, hyperactivity, and impulsivity that cause functional
impairment. Recent research indicates that symptoms persist into adulthood in the majority
of cases, with prevalence estimates of approximately 5% in the school age population and
2.5%–4% in the adult population. Although students with ADHD are at greater risk for academic
underachievement and psychosocial problems, increasing numbers of students with ADHD are
graduating from high school and pursuing higher education. Stimulant medications are considered the first line of pharmacotherapy for individuals with ADHD, including college students.
Although preliminary evidence indicates that prescription stimulants are safe and effective for
college students with ADHD when used as prescribed, very few controlled studies have been
conducted concerning the efficacy of prescription stimulants with college students. In addition,
misuse of prescription stimulants has become a serious problem on college campuses across
the US and has been recently documented in other countries as well. The purpose of the present systematic review was to investigate the efficacy of prescription stimulants for adolescents
and young adults with ADHD and the nonmedical use and misuse of prescription stimulants.
Results revealed that both prostimulant and stimulant medications, including lisdexamfetamine
dimesylate, methylphenidate, amphetamines, and mixed-amphetamine salts, are effective at
reducing ADHD symptoms in adolescents and adults with ADHD. Findings also suggest that
individuals with ADHD may have higher rates of stimulant misuse than individuals without the
disorder, and characteristics such as sex, race, use of illicit drugs, and academic performance
are associated with misuse of stimulant medications. Results also indicate that individuals both
with and without ADHD are more likely to misuse short-acting agents than long-acting agents.
These findings have implications for intervention, prevention, and future research.
Keywords: ADHD symptomatology, pharmacotherapy, nonmedical stimulant use, lisdexamfetamine, methylphenidate, amphetamine
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Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder
characterized by symptoms of inattention, hyperactivity, and impulsivity that cause
functional impairment.1 Previously, ADHD was believed to be primarily a disorder
of childhood that would be outgrown with the onset of puberty. Recent research,
however, indicates that symptoms persist into adulthood in the majority of cases, with
prevalence estimates of approximately 5% in the school age population and 2.5%–4%
in the adult population.1–4 Academic problems are prevalent among children and
adolescents with ADHD and are associated with inattention and difficulty remaining seated, following directions, and completing assignments.5 In addition, children
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and adolescents with ADHD often demonstrate disruptive,
defiant, and hostile behavior.6,7 Given these academic and
behavioral difficulties, children and adolescents with ADHD
are more likely than their non-ADHD peers to receive lower
grades, fall behind academically, receive special education
services, repeat grades, and drop out of high school and are
less likely to pursue college.5,8 Research suggests, however,
that the symptoms of ADHD are often manifested differently
in adolescence compared with in childhood. For example,
symptoms of hyperactivity tend to decrease in adolescence
relative to childhood and instead may be manifested as symptoms of cognitive or internal restlessness.9–11 Adolescents with
ADHD, however, continue to demonstrate similar levels of
impairment as younger children with ADHD, including academic underachievement and difficulties with peers and social
relationships, as well as various high-risk behaviors, including
reckless driving and sexual behavior and substance use.12
Despite these impairments, students with ADHD are
increasingly graduating from high school and attending
college.13 However, information is lacking concerning the
exact prevalence of ADHD among college students, due to
privacy protection for students with disabilities under the
Americans with Disabilities Act of 1990 and because many
college students who meet diagnostic criteria for ADHD may
not have been diagnosed with the disorder.14,15 Therefore,
more information is sorely needed regarding the prevalence
of the disorder in the college population and its impact on
student functioning. Several investigations have examined the
prevalence of ADHD and the functioning of college students
with ADHD symptomatology, most of which have relied on
student self-report. For example, Weyandt et al16 conducted the
first study assessing ADHD symptomatology among college
students and found that approximately 2.5%–8.7% of participants reported significant ADHD symptoms, depending on the
criteria employed. More recent estimates are similar to those
of Weyandt et al, indicating that approximately 2%–10% of
college students have significant ADHD symptoms and that
approximately 50% of students who receive disability services
do so because of ADHD.15,17–19
In terms of the academic and psychosocial functioning of
college students with ADHD, Norwalk et al20 found that students with ADHD had greater difficulty with college adjustment and poorer study habits and study skills than students
without the disorder. Similarly, Shaw-Zirt et al21 found that
college students with ADHD, matched with non-ADHD peers
on age, sex, and grade point average (GPA) (a measure of
academic performance), reported poorer academic, social,
and emotional adjustment than non-ADHD participants.
Other studies have revealed that college students with ADHD
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tend to have lower GPAs, higher rates of academic probation,
and poorer test-taking strategies and are less likely to graduate from college.2,22–24 Self-reported psychological distress
also appears to be more common among college students
with ADHD than among those without the disorder, including poorer self-esteem and increased levels of depression
and anxiety.21,25–27 Collectively, these findings indicate that
students with ADHD and elevated ADHD symptomatology
are beset by various challenges in the college environment.
To improve the outcomes of college students with ADHD,
proper identification of the disorder is crucial so that effective prevention and intervention strategies may be developed
and implemented.

Medical and nonmedical use
of prescription stimulants
Pharmacotherapy is the primary treatment option for
children, adolescents, and adults with ADHD, including
college students.28,29 US Food and Drug Administration
(FDA)-approved medications for ADHD include 1) stimulants such as methylphenidate (MPH) (eg, Ritalin [Novartis
International AG, Basel, Switzerland], Concerta [Janssen
Pharmaceuticals Inc., Titusville, NJ, USA]), dextroamphetamine (D-AMP) (eg, Adderall [Shire plc, Dublin, Ireland],
Dexedrine [GlaxoSmithKline plc, London, UK]), and
lisdexamfetamine dimesylate (LDX) (eg, Vyvanse [Shire
Inc., Wayne, PA, USA]), a prostimulant; and 2) nonstimulants (eg, atomoxetine, [Strattera; Eli Lilly and Company,
Indianapolis, IN, USA]).
Nonstimulants (eg, atomoxetine) have been demonstrated
to be safe and effective for improving ADHD symptoms
among children, adolescents, and adults.30–33 Nonstimulants
have been found to be effective for individuals who do not
respond to stimulants and have also been recommended for
treating patients with ADHD who have comorbid substance
use disorder (SUD). Nonstimulants, unlike stimulants, primarily affect the norepinephrine neurotransmitter system
rather than the dopaminergic system and consequently have
a lower potential for abuse than stimulant medications.
Stimulant medications, however, remain the first line of
pharmacotherapy for individuals with ADHD.28,29,32 An
extensive body of literature attests that stimulant medication,
when used as prescribed, is safe and efficacious for improving attention and decreasing hyperactivity and impulsivity
symptoms.34–42 Although individuals with ADHD may greatly
benefit from prescription stimulant medication, given their
abuse potential when not taken as prescribed, prescription
stimulants have been classified as schedule II medications by
the FDA. A schedule II classification indicates that although
Psychology Research and Behavior Management 2014:7
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the medication has been approved for medical use, it has a
high potential for abuse, which, in turn, may lead to physio
logical and/or psychological dependence.43
Numerous studies have documented that the nonmedical use of prescription stimulants, defined here as the use of
stimulant medication in the absence of a valid prescription
and use of prescription stimulants other than as prescribed,
is a growing problem on college campuses, and college
students typically report that stimulant medication is easy
to obtain on campus.44–52 Indeed, large numbers of students
claim to have engaged in the nonmedical use of prescription
stimulants, which is reflected in lifetime prevalence rates of
prescription stimulant misuse ranging from 5% to nearly
34% of students.53,54 Researchers have speculated that this
increase may, in part, be explained by increasing numbers
of college students receiving stimulant medication treatment
for ADHD who may be distributing their medication to their
peers, who may, in turn, misuse it.44,49 Due to the significant
health risks associated with the nonmedical use of prescription stimulants, this behavior poses a serious public health
issue.55 Consequently, studies have attempted to elucidate the
characteristics of prescription stimulant misuse as well as risk
and protective factors associated with this behavior.
The most commonly reported and the most strongly
endorsed reason for taking prescription stimulants nonmedically is to improve attention and alertness while studying,
taking exams, and writing papers: ie, cognitive and academic
enhancement.44,45,49,52,53 Research has also identified several
risk factors for stimulant misuse, including demographic
variables such as sex, ethnicity, and psychological risk
factors, such as depressive symptomatology and symptoms
of inattention. The identification of malleable predictors such
as the academic and psychosocial functioning of students is
particularly important for prevention and intervention strategies for prescription stimulant misuse.56–58

Purpose of the present study
Given the positive association between psychological factors,
ADHD symptoms, and the nonmedical use of prescription stimulants, and that college students report misusing
stimulants primarily to enhance their cognitive and academic
functioning, it is highly plausible that, by doing so, students
are trying to compensate for the struggles they encounter
in the college environment. In fact, some researchers have
hypothesized that college students may be using prescription
stimulants nonmedically as a coping strategy to treat ADHD
symptoms: ie, to “self-medicate”.49,57 Although preliminary
evidence indicates that prescription stimulants are safe and
effective for college students with ADHD when used as
Psychology Research and Behavior Management 2014:7

Pharmacological interventions for adolescents and adults with ADHD

prescribed, very few controlled studies have been conducted
on the efficacy of prescription stimulants for college student
functioning specifically.37 The question that arises, then, is
whether the medical use of prescription stimulants leads to
reductions in symptoms and improved academic and psychosocial outcomes. Further, is the medical use of prescription
stimulants associated with increased nonmedical use of these
medications? What is the scope of prescription stimulant
misuse among college students? Are certain types of medications associated with greater potential for misuse than others?
Answers to these questions will greatly inform both the treatment of ADHD among college students and prevention and
intervention efforts aimed at reducing the nonmedical use of
prescription stimulants on college campuses.
The present study attempted to answer these questions
by conducting a systematic review of the literature concerning studies that investigated 1) the efficacy of prescription
stimulants for adolescents and adults, including college
students, with ADHD and 2) the nonmedical use and misuse
of prescription stimulants.

Methods
Search and retrieval
A systematic literature review was conducted according
to Okoli and Schabram’s59 eight-step guide. Accordingly,
all researchers were trained in the protocol for searching
and identifying relevant articles. Although the first study
to identify stimulant misuse was conducted in 2000 by
Babcock and Byrne,46 a substantial number of studies
addressing stimulant misuse appeared in 2002. Therefore,
we attempted to identify and retrieve all empirical studies
published after 2002 that examined the efficacy of stimulants
and nonstimulants and stimulant misuse with adolescents
and adults. The search and retrieval process included a comprehensive search of the following bibliographic databases:
PsycINFO, PsycARTICLES®, MEDLINE, and ScienceDirect. Keywords and eligibility criteria were established
separately for each subject. In order to identify and retrieve
empirical studies that examined the efficacy of stimulants
among adolescents and adults, the following keywords
were used: “efficacy” + “stimulants”, “efficacy” + “Ritalin”,
“efficacy” + “Adderall”, “efficacy” + “Concerta”, “ADHD” +
“Ritalin”, “ADHD” + “Adderall”, and “ADHD” + “Concerta”.
Keywords used to identify research examining the efficacy
of nonstimulants and prostimulants among adolescents
and adults included the following: “efficacy” + “nonstimulants”, “efficacy” + “Strattera”, “efficacy” + “Vyvanse”,
and “efficacy” + “prostimulant”. Finally, keywords used
to identify research examining stimulant misuse among
submit your manuscript | www.dovepress.com
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adolescents and adults were: “prescription stimulant” +
“misuse”, “prescription stimulant” + “illicit”, “methylphenidate” + “misuse”, “methylphenidate” + “illicit”, “prescription
stimulants” + “nonmedical”, and “methylphenidate” +
“nonmedical”.

Eligibility criteria
Studies for all search subjects were selected for review based
on the following criteria.
1. The study was published in English.
2. The study was published no earlier than 2002.
3. The study included a minimum sample size of
20 subjects.
4. The study used an original dataset (meta-analyses and
reviews were excluded).
5. T h e s t u d y wa s r e l a t i o n a l , ex p e r i m e n t a l , o r
quasiexperimental.
6. The study could be conducted worldwide.
7. The sample included adolescents (ie, participants with a
mean age of $12 years) and/or adults. Note that studies
including both children and adolescents were included if
the mean age of participants was $12 years. Studies that
did not report the participants’ mean age and included
samples with a majority of participants aged ,12 years
were excluded.
8. The sample included human subjects only and included
no special groups except for persons with ADHD and
learning disabilities.
9. The study used only FDA-approved medication
for ADHD.
10. Eligibility criteria were established specif ically
for research examining the efficacy of stimulants,
prostimulants, and nonstimulants.
11. The sample included a control group (guanfacine studies
were excluded, as well as studies examining efficacy of
nicotinic agonists).

Results
The search process resulted in identifying 2,103 sources, of
which 76 met eligibility criteria. Specifically, nine studies
examined the efficacy of LDX, 14 explored the efficacy of
MPH, three assessed the efficacy of amphetamine (AMPH),
three explored the efficacy of both MPH and AMPH in
adolescents and adults, and 47 examined stimulant misuse
among adolescents and adults. Although included in the
initial search process, no studies examining the efficacy
of nonstimulants met eligibility criteria for the present
review.
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Efficacy of prostimulants
for adolescents and adults
As seen in Table 1, all of the included studies (n=9)
demonstrated a significant improvement in the measured
outcomes from LDX compared with placebo. Six of the nine
included studies reported effect sizes, all of which (based
on Cohen’s estimates of small, medium, and large) reported
medium to large LDX-related effects for improvement in
ADHD and related symptoms.35,37,60–64 Although the majority
of studies examined LDX effects among adults, only one
study examined its efficacy among a sample of adolescents.
Specifically, Findling et al65 reported that at varying doses
(30, 50, and 70 mg/day), LDX was more effective at treating ADHD than placebo. Regarding adults with ADHD,
improvements from LDX have been reported for quality of
life, performance productivity, and executive function.35,64,66
Large effects from LDX on improved executive function
were also demonstrated in college students with and without
ADHD.37 Furthermore, LDX was associated with reduced
ADHD symptoms compared with placebo in a sample of
college students and two different samples of adults.37,61,62
Although higher doses of LDX related to greater improvement in the reduction of ADHD symptoms in two studies, in
one study differences between doses were not observed.37,61,62
The maintenance of efficacy of LDX compared with placebo
during a 2-week randomized withdrawal phase was also demonstrated to be effective in a sample of adults with ADHD.67
Finally, findings suggest that LDX may be effective for
treating individuals with comorbid ADHD and depression
or SUD and in reducing ADHD symptoms.63
The most common side effects reported by participants
in studies investigating the efficacy of LDX included a
decreased appetite, weight loss, dry mouth, insomnia, nausea, diarrhea, dizziness, headache, nasal congestion, feeling
jittery, and anxiety. Mild to moderate adverse treatmentrelated effects were generally reported by 5% or fewer treatment group participants and included insomnia, tachycardia,
irritability, fatigue, increased blood pressure/hypertension,
upper respiratory tract infections, anxiety, decreased libido,
and dyspnea. No deaths were reported in any of the studies.
The results of most LDX studies led to the conclusion that
the drug has a safety profile consistent with previous studies
and other long-acting stimulants.

Efficacy of MPH and AMPH
for adolescents and adults
Although research examining the efficacy of LDX is in its
early stages, numerous studies have examined the efficacy

Psychology Research and Behavior Management 2014:7

Clinician-determined
ADHD-RS total score

BRIEF-A scales (GEC,
index, and clinical
subscales)
AIM-A (quality of life
measure) and CGI-S/
CGI-I

ADHD-RS-IV, CGI-S

Self-report rating scales
of functioning and direct
assessment of ADHD
symptoms, verbal
learning/memory, and
adverse side effects
ADHD-RS, CGI-I, and
CGI-IS

61

35

67

37
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ADHD-RS-IV, CGI-I,
and YQOL-R

ADHD-RS, CGI-I

65

63

62

66

Measures

Reference

30, 50, or
70 mg/day

30, 50, or
70 mg/day

30, 50, or
70 mg/day

30, 50, or
70 mg/day

30, 50, or
70 mg/day

30–70 mg/day

30, 50, or
70 mg/day

30, 50, or
70 mg/day

Doses of
LDX

N=53

N=314

N=420

N=50

N=116

N=142

N=161

N=420

N

Adults with ADHD
aged 18–55 years

Adolescents with
ADHD aged
13–17 years

Adults with ADHD
aged 18–55 years

College students
with and without
ADHD aged
$18 years

Adults with ADHD
aged 18–55 years

Adults with ADHD
and EF deficits
aged 18–55 years
Adults with ADHD
aged $18 years

Adults with ADHD

Groups

Randomized, double-blind,
placebo-controlled, forced-dose
titration study

4-week, forced-dose titration,
double-blind study

4-week, randomized, double-blind,
placebo-controlled, parallelgroup, forced-dose titration
study

4-week, open-label, doseoptimization phase followed by
a randomized, double-blind,
multicenter, placebo-controlled,
2-way crossover phase
3-week open-label phase at a
stable LDX dose, 6-week doubleblind, randomized, withdrawal
phase on treatment with LDX
(same dose) or placebo
Double-blind, placebocontrolled, crossover study

Randomized, double-blind,
placebo-controlled study

Double-blind, placebocontrolled study

Design

Table 1 Studies investigating the efficacy of lisdexamfetamine dimesylate (LDX) for adolescents and adults (N=9)

LDX intake was associated with large
reductions in ADHD symptoms and
improved EF compared with placebo.
Higher LDX doses associated with
greater symptom reduction and EF
improvement
LDX more effective than placebo at
reducing ADHD symptoms; higher
doses related to greater improvement;
response not affected by prior
pharmacotherapy
LDX at all doses was more effective
than placebo in treating ADHD
symptoms, with a trend for greater
rates of improvement with increasing
doses
LDX was effective at treating ADHD
symptoms among individuals with and
without comorbid depressive or
substance use disorders. No dosage
effects were reported

Individually optimized LDX dose intake
demonstrated maintenance of efficacy
compared with placebo during a
2-week randomized withdrawal phase

Individually optimized LDX intake
associated with increased quality of life

All three LDX doses were more
effective than placebo in the treatment
of ADHD, with improvement in ADHD
symptoms observed within 1 week.
No differences between doses were
observed
Individually optimized LDX intake was
associated with improvement in EF

Conclusion
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(Continued)

d for LDX efficacy for
participants without a history
of depression =0.58 (CI -0.37,
1.53) and with a history of
depression =0.86 (CI 0.57, 1.14)

Effect of LDX on ADHD
symptoms: partial η2=0.30
(inattention/memory problems)
and 0.41 (hyperactivity/
restlessness) and EF (global EF):
partial η2=0.26
d for effect size of LDX relative
to placebo ranged from ≈0.9
to 2.0, with stronger effects
for greater baseline symptom
severity
Not reported

Not reported

Not reported

d for GEC =0.74a

d=0.73, 0.89, and 0.99 for
30, 50, and 70 mg doses,
respectivelya

Effect sizes

Dovepress
Pharmacological interventions for adolescents and adults with ADHD
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Note: aArticle did not report exact type of effect size, but based on calculations we interpreted it as Cohen’s d.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS, ADHD Rating Scale; ADHD-RS-IV, ADHD Rating Scale IV; AIM-A, ADHD Impact Module for Adults; BRIEF-A, Behavior Rating Inventory of Executive FunctionAdults; CGI-I, Clinical Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity; CI, confidence interval; d, Cohen’s d; EF, executive function; GEC, Global Exeuctive Composite; LDX, lisdexamfetamine dimesylate;
PERMP-A, Permanent Product Measure of Performance-Attempted; PERMP-C, Permanent Product Measure of Performance-Correct; YQOL-R, Youth QOL-Research Version.

Overall least-squares mean
model-based effect sizes for
LDX effect on PERMP-A =0.9
and PERMP-C =0.8
Medium to large effect sizes of
performance-based measures of
productivity, suggesting attention
increased as a result of individually
optimized doses of LDX
Open-label dose-optimization and
randomized, placebo-controlled,
double-blind, 2-way crossover
phases
Adults with ADHD
aged 18–55 years
N=103
(initial N=142)
30, 50, and
70 mg/day
PERMP-A and PERMP-C
and ADHD-RS-IV
64

Measures
Reference

Table 1 (Continued)

Doses of
LDX

N

Groups

Design

Conclusion

Effect sizes

Weyandt et al
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of MPH, AMPH, and mixed amphetamine salts (MAS). The
included research studies examined the effects of these stimulants among samples of adolescents (n=5), one of which also
included children, and adults (n=15) (see Table 2). The vast
majority of studies (n=14) specifically examined the effects
of some form of MPH, whereas three studies examined MAS,
and the remaining studies (n=3) examined a combination of
MPH and MAS or AMPH. Regardless of the medication
examined, all of the included studies reported statistically significant positive effects for stimulant medication compared
with placebo, and effect sizes ranging from small to large
based on Cohen’s estimates of effect size.60 A total of 14 out
of 20 included studies reported effect sizes. Of the studies
reporting effect sizes for positive effects from stimulant
medication, most effect sizes ranged from medium to large,
with two studies reporting small to medium effects.40,68–77 One
study reported effect sizes regarding the interaction effects
of differences between sex and medication dose, with no
significant interactions found. Effect sizes ranged from very
small (partial η2 as low as 0.00) to small.78
Studies assessing the effects of MPH, dextroamphetamine extended release (d-MPH-ER), MPH long-acting
or extended release (MPH-ER), multilayer-release MPH,
and MAS, including triple-bead MAS and MAS extended
release (MAS-ER), have demonstrated reductions in ADHD
symptoms among adult samples.34,40,69–72,74–76,79–82 For example,
Biederman et al83 reported that adults with ADHD taking
osmotic release oral system (OROS)-MPH, compared with
those taking a placebo, demonstrated reduced symptoms of
inattention and hyperactivity/impulsivity specifically. Adolescents taking MAS-ER and MPH-ER have also been shown
to demonstrate reduced ADHD symptoms.73,84
Regarding the effective dose for improvements in
ADHD symptoms, doses of MPH-ER of 36–108 mg/day
and 40–80 mg/day have been shown to be effective.34,40
Similarly, two studies reported that higher doses of MPH-ER
and d-MPH-ER were more effective than lower doses at
reducing ADHD symptoms among adults with ADHD.70,74
Among adolescents, higher doses, compared with lower
doses, of d-MPH-ER and MAS-ER have also been shown
to relate to improvement of ADHD symptoms. 75 Rösler
et al,76 however, reported that even at low to moderate doses
(10–60 mg/day), MPH-ER was effective at reducing ADHD
symptoms and that these effects were sustained during a
24-week follow-up.
In addition to ADHD symptoms, studies have shown that
MPH and MPH-ER may improve cognition and emotional
symptoms, and triple-bead MAS may enhance executive

Psychology Research and Behavior Management 2014:7
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CGI-I, Adult ADHD
Up to 1.3 mg/kg/day
Investigator System Report
Scale

Wender–Utah Rating Scale, 10 mg 3 times daily then
Adult ADHD Problem
15 mg 3 times daily
Behaviors, Hamilton
Anxiety Rating Scale, Beck
Depression Inventory,
Wechsler Adult
Intelligence Scale, Conners’
Continuous Performance
Test, stop signal
computerized task
ADHD-RS-IV
40, 60, or 80 mg/day

83

79

69

CGI-I, CGI-IS, and CAARS
self-report and observer
rated

Digit span tasks, Raven’s
Progressive Matrices,TOVA,
decision-making tasks

68

40

36, 54, 72, 90, or
108 mg/day

Adult ADHD Investigator
Symptom Report Scale

34

OROS-MPH

Participants were titrated MLR MPH
to optimal effect over
1–3 weeks followed by
2 weeks of treatment
on a stable dose

MPH-LA

MPH

OROS-MPH

N=50

N=725

N=30

N=141

N=58

N=226

Types of
N
medication

15 mg (10 mg or 20 mg MPH
if low/high body weight)

Doses of medication

Reference Measures

Adults with
ADHD aged
18–60 years

Adults with
ADHD aged
18–60 years

Adults with
ADHD aged
$18 years

Adults, with
ADHD aged
19–60 years

Adults aged
$18 years;
32 with ADHD,
26 non-ADHD

Adults with
ADHD aged
18–65 years

Age group

Double-blind, placebocontrolled, crossover
study

40-week, double-blind,
randomized, placebocontrolled study

Effect sizes

MPH intake associated with
enhanced cognitive
performance, nonspecific to
ADHD

MPH-LA at doses of
40–80 mg/day decreased
ADHD symptoms compared
with placebo at the end of the
9-week double-blind phase of
the study

submit your manuscript | www.dovepress.com

Dovepress

(Continued)

d of all MPH-LA three dose
levels combined was 0.55
for DSM-IV ADHD-RS
(0.55, 0.47, and 0.64 for
MPH-LA 40, 60, and 80 mg,
respectively) and was 0.39
for SDS total score (0.47,
0.25, and 0.43 for MPHLA 40, 60, and 80 mg,
respectively)
Daily MLR MPH intake
Effect size for global
resulted in significant decrease improvement =0.90 (95% CI
in ADHD symptoms compared 0.43–1.36), effect size for the
with placebo
CAARS-A ADHD Index =0.53
(95% CI 0.05–0.99)a

Not reported

d=0.74 for backward version
of digit span task for MPH and
placebo conditions, d=0.53 for
forward version of digit span
task for MPH and placebo
conditions
Not reported

OROS-MPH at 36–108 mg/day Not reported
was effective at decreasing
ADHD symptoms

Conclusion

Double-blind, randomized, MPH was effective at reducing
6-week, placebosymptoms of inattention and
controlled, parallel design hyperactivity/impulsivity
relative to placebo
Double-blind, placeboMPH effective at improving
controlled, crossover trial ADHD symptoms compared
with placebo

Randomized, placebocontrolled, double-blind,
parallel group, doseescalation study
Randomized, double-blind,
placebo-controlled study

Design

Table 2 Studies investigating the efficacy of methylphenidate (MPH) and/or amphetamine for adolescents and adults (N=20)
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ADHD self-report and
parent report ratings,
objective measures of
inattention and hyperactivity/
impulsivity during driving
performance and
neuropsychological tasks
Structured diagnostic
interview for DSM-IV
(SCID-I and Kiddie SADS-E)
ADHD-RS, CGI-I

ADHD-RS, CGI-I

78
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74

ADHD-RS-IV, CGI-I,
Brown Attention Deficit
Disorder Scale, and AIM-A

ADHD-RS-IV, CGI-I and
CGI-S, parent completed
Weiss Functional
Impairment Scale

81

75

73

72

70

ADHD-RS, semistructured
and structured diagnostic
interviews for ADHD and
other disorders
CAARS

80

Reference Measures

Table 2 (Continued)

10, 20, 25–30 mg/day

Starting dose 12.5 mg

20, 30, or 40 mg/day

10, 20, 30, and
40 mg/day

1.1 mg/kg/day

72 mg of OROSMPH, 30 mg of
se-AMPH-ER

18, 36, or 72 mg/day

0.5–1.0 mg/kg/day

Doses of medication

N=402

N=45

Long-acting
d-MPH-ER
and ER-MAS

Triple-bead
MAS

d-MPH-ER

MAS-ER;
Adderall XR

MPH

N=56

N=272

N=184

N=287

N=146

OROS-MPH, N=35
se-AMPH-ER

OROS-MPH

MPH

Types of
N
medication

Conclusion

Double-blind, randomized, MPH was associated with
placebo-controlled study reductions in ADHD symptoms
compared with placebo
4-week, randomized,
MAS-ER treatment for 4 weeks
multicenter, double-blind, was associated with significant
placebo-controlled,
improvements in ADHD
parallel-group, forced-dose symptoms compared with
titration study
placebo
Multicenter, randomized, Higher doses of d-MPH-ER
fixed-dose, double-blind, were associated with increased
placebo-controlled
improvement in ADHD
symptoms compared with
placebo
7-week, randomized,
MAS was more effective in
double-blind, multicenter, treating adult ADHD
placebo-controlled,
symptoms and improving
parallel-group, doseexecutive functioning and QOL
optimization study
than placebo

d=0.53 for 20 mg, 0.49 for
30 mg, and 0.83 for 40 mg of
d-MPH-ER

d=0.78 for differences in
ADHD symptomatology
between MAS-ER and placebo
groups

d=1.41 for the difference
between MPH and placebob

Not reported

d for the 18, 36, and 72 mg PR
MPH groups was 0.38, 0.43,
and 0.62, respectivelyb

Not reported

Effect sizes

24.5 versus placebo 5.7;
P,0.0001, least-squares mean
difference, 18.8 for performance
and daily functioning subscale
of AIM-A QOL between triplebead MAS and placebo
Children and
8-week, double-blind,
d-MPH-ER and MAS-ER were r2= 0.59 and 0.46, respectively,
adolescents with crossover study comparing associated with significant
for dose-related decreases in
ADHD aged
d-MPH-ER and MAS-ER
reductions in ADHD
total and hyperactive symptom
9–17 years, mean
symptoms. Improvement was scores that did not differ by
age 11.7 years
associated with larger doses
stimulant. r2=0.11 for decreases
rather than type of medication of inattention symptoms that
did not differ by stimulant

Adults with
ADHD aged
18–55 years

Adults with
ADHD aged
18–60 years

Adults with
ADHD aged
19–60 years
Adolescents with
ADHD aged
13–17 years

Randomized, placebocontrolled, double-blind,
crossover trial

Design

MPH demonstrated to be
effective at reducing ADHD
symptoms compared with
placebo
Adults with
Double-blind, randomized, OROS-MPH intake resulted in
ADHD aged
placebo-controlled,
decrease in ADHD symptoms
18–63 years
parallel-group, fixed-dose compared with placebo. Larger
trial at 51 sites
doses were associated with
greater symptom reduction
Adolescents with Randomized, doubleEfficacy of extended-release
ADHD aged
blind, placebo-controlled, stimulants for treating ADHD
16–19 years
crossover study
symptoms found to be
equivalent for males and
females

Adults with
ADHD aged
$18 years

Age group

Weyandt et al
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WRAADDS, 6-item
Emotional Lability Scale
from the CAARS:S:L,
Symptom Checklist-90-R

ADHD-RS and CAARS
(short self-report)

77

82

Investigator, parent, and
adolescent assessments
of ADHD-RS

WRAADDS

76

84

WRAADDS, ADHD
Diagnostic Checklist,
CAARS, CGI, and SDS

71

18, 36, 54, or 72 mg/day

Medication was titrated
twice/day for ﬁrst
5 weeks by use of a
ﬂexible dose schedule
to a maximum dose of
60 mg/day, starting with
10 mg/day. Minimum
maintenance dose after
5 weeks was 20 mg/day
20, 40, or 60 mg/day

10–60 mg/day

Two daily individually
body weight-adjusted
doses up to 1 mg/kg
per day

OROS-MPH

MAS-ER

MPH-ER

MPH-ER

MPH-ER

N=177

N=255

N=363

N=249

N=162

Randomized, placebocontrolled trial

Randomized, multicenter,
24-week, double-blind,
placebo-controlled study

Multicenter, double-blind,
randomized, placebocontrolled, 24-week study
with parallel-group design

Double-blind, randomized,
placebo-controlled study
with parallel-group design
conducted at 10 sites

Adolescents with Multisite study; 1-week
ADHD aged
washout phase, an
13–18 years
open-label dose titration
phase lasting up to
4 weeks, a 2-week doubleblind phase consisting of a
randomized comparison
of an OROS-MPH vs
placebo, and 8-week openlabel follow-up safety
phase of OROS-MPH

Adults with
ADHD aged
$18 years

Adults with
ADHD aged
$18 years

Adults with
ADHD aged
$18 years

Adults with
ADHD aged
$18 years

MAS-ER was effective at
reducing ADHD symptoms,
with effects lasting for up to
12 hours at a time. Symptom
reduction was greatest for
highest dose for those with
severe symptoms
OROS-MPH (individually
titrated) was found to
significantly reduce ADHD
symptoms among adolescents
compared with placebo

MPH-ER was associated
with improved emotional
symptoms as well as
obsessive–compulsive
symptoms and problems
with self-concept

MPH-ER treatment in low
to moderate doses was
effective at reducing ADHD
symptoms; effectiveness
sustained at a 24-week
follow-up

MPH-ER was more effective
than placebo at treating
ADHD symptoms in adults,
based on both self- and
investigator ratings

Not reported

(Continued)

d=0.59 for differences between
MPH-ER vs placebo. d=0.68
was reported for attention
difficulties. Effects were also
reported for hyperactivity
d=0.51 and hyperactivity/
impulsivity d=0.46
d=0.39 for overall ADHD
symptoms. Significant treatment
effects in favor of MPH-ER were
found: inattention (d=0.41),
hyperactivity (0.30), hot temper
(0.33), affective lability (0.19),
emotional overreactivity
(0.45), disorganization (0.31),
impulsivity (0.27)
d=0.37 for low MPH-ER
treatment of inattention,
hyperactivity, and impulsivity.
Effects for the ITT and PP
populations =0.30 and 0.46,
respectively, for obsessive–
compulsive symptomatology
and 0.29 and 0.40 for selfconcept
d for MAS-ER =0.8b
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Notes: aArticle did not report exact type of effect size or calculations; barticle did not report exact type of effect size, but based on calculations we interpreted it as Cohen’s d.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS, ADHD Rating Scale; ADHD-RS-IV, ADHD Rating Scale IV; AIM-A, ADHD Impact Module for Adults; CAARS, Conners’ Adult Attention Deficit Disorder
Scale; CAARS:S:L, Conners’ Adult ADHD Rating Scale: Self-report: Long; CGI-I, Clinical Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity; CI, confidence interval; d, Cohen’s d; d-MPH-ER, dexmethylphenidate
extended release; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; OROS, osmotic release oral system; MAS, mixed amphetamine salts; MAS-ER, mixed amphetamine salts extended release; MLR, multilayer
release; MPH, methylphenidate; MPD-ER, methylphenidate extended release; MPH-LA, methylphenidate long acting; QOL, quality of life; SADS-E, Schedule for Affective Disorders and Schizophrenia - Epidemiologic version; SDS, Sheehan
Disability Scale; SCID-I, Structural Clinical Interview for DSM-IV; se-AMPH-ER, extended-release amphetamine salts; TOVA, test of variables of attention; WRAADDS, Wender–Reimherr Adult Attention Deficit Disorder Scale; XR,
extended release.

Not reported
Intake of both OROS-MPH
and AMPH-ER was
associated with improved
neuropsychological functioning
compared with placebo
Adolescents with Randomized, doubleADHD aged
blind, placebo-controlled
16–19 years
study
Go/no-go task measuring
inhibition and the Delayed
Matching-to-Sample task
(nonexecutive visual
memory)

72 mg OROS-MPH,
30 mg Adderall XR

OROS-MPH N=35
or se-AMPHER (Adderall
XR)

232

85

Reference Measures

Table 2 (Continued)

Doses of medication

Design
Age group
Types of
N
medication

Conclusion

Effect sizes

Weyandt et al
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functions and quality of life among adults.68,77,81 For example,
Rösler et al77 reported on a multicenter 24-week study and
found that among a sample of adults with ADHD, taking
MPH-ER was associated with improvement in emotional
symptoms, obsessive–compulsive symptoms, and problems
with self-concept. Among adolescents, one study reported
that within a sample of 35 adolescents, those taking either
OROS-MPH or amphetamine extended release (AMPH-ER)
(Adderall XR) demonstrated improved neuropsychological
functioning compared with those taking placebo.85 Finally,
MPH-ER and AMPH-ER have been demonstrated to be
equally effective at improving symptoms among male and
female adolescents with ADHD.78
Regarding side effects in studies investigating the efficacy
of D-AMP and MPH, participants most commonly reported
decreased appetite, weight loss, headache, insomnia, abdominal pain, dizziness, nervousness, emotional lability, and dry
mouth. Approximately half of the studies (n=12) found that
a majority of participants reported at least one side effect;
however, mild to moderate adverse treatment-related effects
were generally reported by #5% treatment group participants and included decreased weight, insomnia, tachycardia,
palpitation, irritability, fatigue, increased blood pressure/
hypertension, and anxiety. No deaths were reported in any
of the studies. The results of most stimulant studies led to
the conclusion that the drug has a safety profile consistent
with previous research.86

Stimulant misuse among
adolescents and adults
The efficacy of prescription stimulants among adolescents
and adults with ADHD has been well documented, but the
effects of these medications among populations without
ADHD are unclear. Despite a lack of empirical evidence
of stimulant effectiveness in individuals without ADHD,
numerous studies have documented the misuse of prescription stimulants among college students without the disorder.
Indeed, the present review retrieved more research studies
pertaining to stimulant misuse (n=47) than the combined
number of included studies assessing the efficacy of LDX,
MPH, AMP, and MAS combined (see Table 3). The primary
foci of the retrieved studies examining stimulant misuse
varied. For example, some studies reported on prevalence
rate estimates, others examined characteristics of individuals
most susceptible to stimulant misuse, and others reported
primarily on student opinions, such as ethical implications of
stimulant misuse. Most of the studies, however, reported on
some combination of these factors. Therefore, a systematic

Psychology Research and Behavior Management 2014:7
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Self-report ratings scales of
substance use, stimulant use,
and ADHD symptoms,
Sensation Seeking Scale,
Frost Multi-Dimensional
Perfectionism Scale
Internal Restlessness Scale,
Depression Anxiety Stress
Scales-21, Stimulant Survey
Questionnaire
Self-report rating scales
of weight loss behaviors,
motivations for weight loss,
stress-related eating, selfesteem, and eating disorder
symptoms
National Survey on Drug Use
and Health

Stimulant Survey Questionnaire,
Perceived Stress Scale, Sensation
Seeking Scale, National College
Health Assessment
Brief Symptom Inventory,
Internal Restlessness Scale,
Sensation Seeking Scale,
Stimulant Survey Questionnaire

128

117

89

44

93

100

Structured face-to-face
interview, self-report rating
scale of ADHD symptoms

Monitoring the Future survey

94

47

Measures

Reference

MPH

Ritalin, Concerta,
Metadate, Adderall,
Dexedrine

Ritalin, Concerta,
Metadate, Adderall,
Dexedrine

Adderall, Ritalin,
Dexedrine, MPH,
dextroamphetamine

Adderall, Ritalin

Adderall, Ritalin

Prescription
stimulants

Adderall

Stimulant
description

Table 3 Illicit stimulant use and misuse by adolescents and adults (n=47)

N=66

N=390

N=165

N=443,041

N=705

N=1,033

N=1,153

N=21,137

N

College students who reported misusing
had higher levels of internal restlessness and
psychological distress compared with those
who did not report misuse. No significant
difference was found between sex and
stimulant misuse
Misuse of MPH was associated with other
illicit substance use and diversion among
a sample of adults with prescriptions for
stimulant medication

Misuse of stimulants appears to be
adopted by individuals already engaged in
broader patterns of drug abuse and
nonmedical use
Students with ADHD reported higher rates
of both prescription stimulant use and misuse
compared with students without ADHD

College students may be misusing stimulants
for weight loss, which may be related to
other problematic weight loss strategies

Students who were members of fraternities
and sororities reported higher rates of misuse
compared with nonmembers

High-contact sports may influence male
students to misuse stimulants as
performance enhancers either on or off the
playing field
Nonmedical and medical misusers had a higher
prevalence of using and combining other
substances, as well as greater reports of side
effects compared with appropriate users

Conclusion

Adults aged $18 years

Undergraduates aged
$18 years

Undergraduates aged
#18 years; ADHD

Adolescents and adults
aged #12 years

Undergraduates

Undergraduates aged
$18 years; fraternities
and sorority members

Undergraduates aged
18–25 years

Adolescents aged
13–17 years

Participants

29%

(Continued)

7.5% (past month)

11.5% occasionally
misuse; 1.4%
frequently misuse

3.4%

11.7% (misuse to lose
weight)

19.8%

Prevalence (lifetime
if not otherwise
indicated)
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234
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Structured face-to-face interview

Self-report ratings of prescribed
stimulant use, diversion of
prescribed stimulants, illicit use
of prescribed stimulants, heavy
episodic drinking, monthly alcohol
use, monthly cigarette use, annual
marijuana use, annual ecstasy use
Schedule for Affective Disorders
and Schizophrenia for School-Age
Children-Epidemiologic Version,
Structured Clinical Interview for
DSM-IV, self-report questionnaire
about stimulant medication
misuse and diversion

118

92
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84

129

Drug Abuse Screening Test, selfreport ratings of nonmedical use
of prescription stimulants, past
year other drug use, routes of
administration
National Survey on Drug Use and
Health

Measures

102

Reference

Table 3 (Continued)

Stimulants

Ritalin, Dexedrine,
Adderall

MPH

Adderall, Ritalin,
Dexedrine, Cylert,
DextroStat,
Concerta, MPH,
dextroamphetamine

Ritalin, Dexedrine,
Adderall, Concerta,
MPH

Stimulant
description

N=98 (ADHD
n=55; no
ADHD n=43)

N=1,536

N=100

N=114,241

N=3,639

N

Although the majority of participants with
ADHD used their medications appropriately,
these participants misused and diverted
(11%) their prescription medications at
higher rates than participants without
ADHD in a sample of adults taking
prescribed medications. All of the
participants with ADHD who diverted
their medication and 83% of those who
misused their medications were comorbid
for conduct disorder or substance use
disorder. Immediate-release stimulants
(MPH and mixed amphetamine salts) were
the most common medications. Participants
with ADHD reported misusing/diverting;
however, extended release was not as
prevalent in the included sample

College students who reported misusing
prescription stimulants were more likely to
report using other substances compared with
nonmisusers. Sex not significantly associated
with misuse
Past-year prescription stimulant misuse was
more prevalent among persons aged
12–25 years and among whites. Prevalence in
large metropolitan areas was lower than, or
similar to, that in less populated areas. About
13% of past-year stimulant misusers met the
survey criteria for dependence or abuse
College students who reported misusing
MPH were more likely to report using other
substances compared with nonmisusers
Students who reported prescription stimulant
misuse reported significantly higher rates of
alcohol and other drug use. Prescription
stimulant misuse was more prevalent among
students with no plans for college

Conclusion

Adolescents and adults;
ADHD

Adolescents aged
10–17 years

College students

Adolescents and adults
aged #12 years

Undergraduates

Participants

22% (participants with
ADHD diagnosis)

4.5%

1.4% (past year)

8.5% (lifetime);
6.0% (past year)

Prevalence (lifetime
if not otherwise
indicated)

Weyandt et al
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Questions about ADHD
treatment and misuse and
diversion of prescribed ADHD
medication, side effects reported
by PCPs, the Adult ADHD SelfReport Scale, and the Sheehan
Disability Scale

Self-report questionnaire
with mostly closed-ended,
multiple-choice questions
about student misuse of
prescriptions drugs, motivation
for nonmedical use, deceptive
practices, frequency of use,
consequences of nonmedical
use, peer group nonmedical
use, and an ethics-probing
vignette
Student Life Survey; Adult
Symptom Rating Scale; Cut
Down, Annoyed, Guilty,
Eye-opener instrument;
Drug Abuse Screening Test
Short Form
Self-report survey that included
questions about smoking status,
illicit drug use, and misuse of
prescription stimulant
medications

111

108

97

119

Pittsburgh Sleep Quality Index

130

Adderall, Adderall
XR, Ritalin, Ritalin
LA, Concerta, Focalin,
Focalin XR, other

Ritalin, Dexedrine,
Adderall, Concerta,
MPH

Adderall, Focalin,
Dexedrine, Desoxyn,
Ritalin, Methylin,
Metadate, Concerta,
Provigil

Ritalin, Adderall,
Dexedrine,
DextroStat, Provigil,
Nuvigil, MPH,
mixed-salt
amphetamines,
dextroamphetamine,
modafinil
ADHD medication

N=545
(ADHD
n=486)

N=1,738

N=372

N=115

N=492

The most common specific medications
were Adderall, Adderall XR, and Ritalin.
Short-acting agents were the most
commonly abused substances, indicating
that the rate of delivery may influence
the abuse potential of stimulants
(immediate release may have more
potential for abuse than extended release)

College students who reported misusing
prescription stimulants were more likely to
report cigarette smoking, binge drinking,
and illicit use of cocaine

,1% of physicians suspected adults of
diversion and 1.9% of adults reported
diversion of stimulant medication.
There was a high level of agreement
between adult patients’ report and
level of PCP distrust regarding use
of taking a higher dose of ADHD
drug than prescribed (79.7%) and
use of ADHD drug combined with
illegal substances (90.5%)
The majority of misusers endorsed taking
prescription stimulants to enhance alertness
or energy (65.9%) or improve academic
performance (56.7%). More than half (55.8%)
of the students perceived stimulant misuse to
be academically dishonest and more than half
(59.9%) believed that it offers an unfair
academic advantage

College students who reported nonmedical
use of prescription stimulants reported worse
subjective and overall sleep quality, as well
as more sleep disturbance compared with
nonusers

Adolescents and adults
aged $13 years;
ADHD

Undergraduates aged
$18 years; past-year
prescribed stimulant
users

Medical, pharmacy, and
respiratory therapy
undergraduate and
graduate students

Adults; ADHD

Undergraduates aged
$18 years

14.3%

(Continued)

40% (past year)

11.3%

14.4%
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49

99

Center for Epidemiologic Studies
Depression Scale, self-report ratings
of nonmedical ADHD medication
use, motivations for nonmedical
ADHD medication use, perceived
effects of nonmedical ADHD
medication use, possible adverse
consequences of nonmedical
ADHD medication use, ADHD
symptoms, nonmedical use of
other medications, alcohol, tobacco,
and drug use

Student Life Survey, self-report
ratings of medically prescribed
use of stimulant medication, illicit
use of prescription stimulants,
diversion of prescription
stimulants, obtaining prescription
stimulants, binge drinking, monthly
alcohol use, annual marijuana use
Adult ADHD Self-Report Scale,
face-to-face interview, selfadministered questionnaires
Self-report questionnaire about
nonmedical use of prescription
stimulants and illicit use of
stimulants

112

57

Questionnaire of students’
experiences, perceptions of
stimulant medication use at their
institution, and use of stimulant
medication for nonmedical
reasons

Measures

109

Reference

Table 3 (Continued)

ADHD medication

Methylphendate,
amphetamines

Adderall, Ritalin,
Concerta

Ritalin, Dexedrine,
Adderall, Concerta

Adderall, Ritalin,
MPH

Stimulant
description

N=3,407

N=1,547
(1,035 pre and
512 university)

N=470

N=9,161

N=243

N

ADHD symptoms, particularly inattention,
were associated with being a nonmedical
user of prescription stimulants
Males and students with poor grades reported
higher lifetime prevalence rates than females
and students with good grades among the
preuniversity students. Friends and relatives
were the main sources for prescription
stimulants and the mean age for first time was
16.6 years and 23.3 years for preuniversity
and university students, respectively
The most frequently reported motive of
nonmedical use of ADHD medication was
to enhance the ability to study. Students
perceived nonmedical use to be beneficial
despite frequent reports of side effects

70% of dental and dental hygiene students
reported nonmedical use of prescription
stimulants to improve attention and/or
concentration. The most commonly reported
stimulant medication used nonmedically was
Adderall (77%). 87% of the students obtained
the medication through friends, and 90% began
using the drug in college
Risk factors for illicit use of prescription
stimulants include being male, white,
a member of a social fraternity or sorority,
Jewish religious affiliation, and having a
lower GPA

Conclusion

Undergraduates

Preuniversity students
aged 18–21 years,
undergraduates aged
20–48 years

Undergraduates aged
$18 years

Undergraduates aged
$18 years

Adults aged
$18 years; dental
and dental hygiene
students

Participants

8.9% (since beginning
college) and 5.6%
(past 6 months)

1.29%, 0.26% (past
year), and 0.06% (past
month)

8.1% and 5.4% (past
year)

12.4%

Prevalence (lifetime
if not otherwise
indicated)

Weyandt et al
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Stimulant Medication Use
Questionnaire

Question survey

National Survey of Drug Use
and Health

Student Life Survey, self-report
ratings of medically prescribed
use of stimulant medication,
illicit use of prescription
stimulants, diversion of
prescription stimulants,
obtaining prescription stimulants

ADHD Rating Scale,
Massachusetts General
Hospital Liking Scale

Stimulant Medication Use
Questionnaire

Adolescent Drug and Alcohol
Diagnosis

48

103

91

113

131
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110

96

Adderall,
Dexedrine, MPH,
dextroamphetamine

Ritalin, Adderall,
Cylert, Dexedrine,
Concerta

OROS-MPH

Ritalin, Dexedrine,
Adderall, Concerta

Ritalin, Concerta,
Metadate, Methylin,
Dexedrine, Adderall,
Desoxyn, Cyclert
Adderall, Adderall XR,
Concerta, Stratera,
Ritalin, Dexedrine
Ritalin, Cylert,
Adderall, Concerta

N=450

N=1,025
(ADHD
n=486)

N=558

N=9,161

N=17,709

N=1,550

N=333

Compared with nonillicit users, illicit users
reported more motives to use, less concern
with ethics and safety of use, and greater
perception of use as socially acceptable
College students who illicitly used
prescription stimulants were more likely to
use other drugs
Adolescents who utilize mental health
treatment and engage in marijuana use and
other illegal drugs have significantly increased
risk for past-year nonmedical prescription
stimulant use
The most frequently reported motives of
illicit use of prescription stimulants were
helping with concentration, increase alertness,
and providing a high. Male students (9.3%)
reported significantly higher lifetime rates than
did females (7.2%). Lifetime rates were higher
for white (9.5%) and Hispanic (8.9%) students
than for African American (2.7%), Asian (4.9%),
or other racial student groups (5.8%)
In a sample of adolescents and adults with
nicotine substance use disorder, adults rated
OROS-MPH as more effective in treating
ADHD, whereas adolescents reported feeling
more depressed when taking OROS-MPH.
Compared with adults, adolescents were
more likely to report having lost pills, the
number of pills lost, and the number of pills
not returned
Motives of misuse or abuse of stimulant
medication included improving attention,
partying, and improving grades. Nearly all
(96%) respondents who misused or abused
and specified a stimulant indicated that
Ritalin was their stimulant medication of
choice, followed by Adderall (2%)
Of adolescents in a substance abuse treatment
center who reported nomedically using MPH
or dextroamphetamine, 88% reported
nonmedical use of MPH. Abusers were less
likely to be attending school and increased
likelihood of having a concurrent eating disorder
Adolescents aged
12–18 years;
substance abuse
disorder

Undergraduate and
graduate aged
$17 years, ADHD

Adolescents aged
$18 years; substance
abuse disorder;
smokers

Undergraduate aged
$18 years

Adolescents aged
12–17 years

College students aged
$18 years

Undergraduates

23%

16.2%

(Continued)

8.1% and 5.4% (past
year)

43% (participants
without ADHD
diagnosis)
1.7% (past year)

20%
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238

Recreational Stimulant Use
Survey

Structured face-to-face interview

Self-report questionnaire including
demographic questions, MPH
information-related questions,
questions about frequency of
MPH use, and questions about
perceptions of MPH rise in use

Prescription Stimulant Expectancy
Questionnaire, Sensation Seeking
Scale, self-report rating scale of
symptoms of ADHD

Question survey, face-to-face
interview

Face-to-face interview

95

105

104

54

56

Measures

52

Reference

Table 3 (Continued)
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Prescription
stimulants

Adderall

Adderall, Ritalin

MPH

MPH,
dextroamphetamine

MPH, amphetamine
salts

Stimulant
description

N=1,253

N=1,811

N=42

N=310

N=162

N=448

N

No statistically significant differences were
found for sex or ethnicity in prevalence of
stimulant misuse. 8% of students reported
selling or giving away their prescription
medication, 63% reported knowing someone
who diverted their medication, and 67%
reported knowing someone who had taken
medication recreationally
In a sample of adolescents in an addiction
treatment setting, patients with a diagnosis
of ADHD more likely to have a lifetime
history of stimulant abuse than those with
no ADHD diagnosis
Iranian medical students reported relatively
low levels of knowledge about MPH; however,
increased time at university was associated
with increased knowledge of MPH. Men
demonstrated higher rates of MPH use than
women and medical students with lower
GPA were more likely to use MPH illegally
than those with higher GPAs. Increased
concentration was cited as the most
common reason for MPH use
Among a sample of students with prescriptions
for stimulants, of those who reported
misusing, 62.8% reported taking a higher dose
than prescribed. Compared with nonmisusers,
misusers of prescription stimulants were
more likely to use a greater number of illicit
substances, and reported higher hyperactivity
symptoms and sensation seeking
Most illegal users reported using ADHD
stimulants primarily in periods of high
academic stress and found them to reduce
fatigue while increasing cognition and memory
Among students across 4 years of college,
frequency of past-year nonmedical use of
prescription stimulants was stable over
time, averaging 11.3 days (SD =15.3) in
year 2, 12.1 days (SD =20.8) in year 3,

Conclusion

College students aged
17–19 years

College students

Undergraduate;
ADHD

Adults aged
18–28 years; medical
students

Adolescents aged
13–20 years;
substance abuse
disorder; ADHD

Undergraduates aged
$18 years

Participants

13.3% at year 1 and
31% by year 4

34% (participants with
no prescription for
ADHD medication)

45.2%

8.7%, 6.5% (past year),
and 1% (past month)

18%

Prevalence (lifetime
if not otherwise
indicated)

Weyandt et al
Dovepress

Psychology Research and Behavior Management 2014:7

Psychology Research and Behavior Management 2014:7

Self-report questionnaire, UPPS-P
Impulsive Behavior, Alcohol Use
Disorders Identiﬁcation Test

Question survey of ADHD
diagnosis, treatment history and
nonmedical use of prescription
stimulants
Patient Health Questionnaire,
self-report ratings of nonmedical
use of prescription stimulants,
routes of administration

Question survey

National Survey on Drug Use
and Health

Standard self-report measures of
substance use

116

106

90

114

98

58

Computer-assisted personal
interview, audio computerassisted self-interview

88

Adderall, Concerta,
Ritalin, Dexedrine

Adderall, Ritalin,
Dexedrine, MPH,
dextroamphetamine,
mixed-salts
amphetamines
Ritalin, MPH

Ritalin, Dexedrine,
Adderall, Concerta,
MPH

Methylphendate,
amphetamine salts

Prescription
stimulants

Adderall, Ritalin,
MPH

N=4,572

N=23,645

N=307

N=3,639

N=388

N=206

N=68,736

White students (11.3%) reported significantly
higher rates of lifetime stimulant misuse than
African American (3.0%) or Hispanic (5.6%)
students. The odds of substance use behaviors
were greater among nonmedical stimulant
users compared with medical users or
individuals who indicated never using
stimulant medication

Of the participants who reported nonmedical
use of prescription stimulants, 39.2% used on
1–2 occasions, 31.6% used on 3–5 occasions,
11.3% used on 6–9 occasions, and 17.9%
used on $10 occasions. Respondents who
misuse frequently (51.4%) or nonorally
(47.7%) had the highest rates of depressed
mood in the past month
Fraternity members who reported
nonmedical use of prescription stimulants
were significantly higher among upper
classmen, those living off-campus, and those
who regularly smoked marijuana
Nonmedical prescription stimulant use was
associated with psychological distress,
sensation seeking, binge drinking, and college
enrolment

and 13.8 days (SD=24.2) in year 4. The main
motive for nonmedical use of prescription
stimulants was studying. Nonmedical use of
prescription stimulants was associated with
lower GPA and alcohol/cannabis disorders
Adults (aged 26–34 years) and whites
reported having misused stimulants more
than other age and racial groups. Ritalin and
other methylphenidates were misused at
higher rates than Adderall
Nonmedical use of prescription stimulants
was associated with increases in lack of
premeditation, sensation seeking, positive
expectancies, and positive evaluations
Medical students appear to be a relatively
high-risk population for nonmedical
prescription stimulant use

High school seniors

Adults aged
18–25 years

College students;
fraternity members

Undergraduates aged
18–25 years

Adults; medical
students

Undergraduates aged
18–24 years

Adolescents and
adults aged $12 years

9.5%

55%

(Continued)

6% (past year)

10.1%

7.1%
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Prescription
stimulants, ADHD
medications

Ritalin, Concerta,
Metadate, MPH

Amphetamines, other
psychostimulants

Adderall, Ritalin,
or other ADHD
medication

Stimulant
description

N=4,297

N=2,087

N=1,115

N=627; 468;
400 (first week
of classes,
midterms, finals,
respectively)

N

11% of students reported using prescription
psychostimulants during medical school. First
experiences were most commonly reported
in college (57%) and in medical school (22%).
Psychostimulant use was associated with
being male and other drug use. Although half
of the sample perceived using psychostimulants
for academic performance enhancement to
be a problem, 21% did not perceive it to be
a problem. The majority (95%) of students
reporting using psychostimulants believed
that academic standing could be improved by
taking psychostimulants
College students reported using MPH
nonmedically for recreational reasons as well
as to improve academic performance. 53% of
the nonmedical users were male. Nearly 74%
of nonmedical users were white
Of participants aged 18–25 years,
4.3% reported nonmedical use of ADHD
medication compared with 1.3% among those
aged 26–49 years. Friends and family members
were the most reported source of ADHD
medication for respondents who did not have
a prescription. The most frequently reported
motive of illicit use of prescription stimulants
was productivity (40%), followed by staying
awake (23%)

Self-report of psychostimulant use and
psychostimulant use measured via campus
wastewater samples were significantly
increased during periods of stress (midterms)
compared with the first week of school

Conclusion

Adults aged
18–49 years

College students aged
18–24 years

Adults aged
20–49 years; medical
students

Undergraduate
students

Participants

7.1% and 2% (past
year)

5.3%

18%

11.7% (Adderall),
8.5% (Ritalin),
5% (both)

Prevalence (lifetime
if not otherwise
indicated)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; GPA, grade point average; LA, long acting; MPH, methylphenidate; OROS, osmotic release
oral system; PCP, primary care physician; SD, standard deviation; UPPS-P, urgency, premeditation, perseverance, sensation seeking, and positive urgency; XR, extended release.

87

Web-based survey

Web-based survey

53

107

Self-report survey addressing
stress, wellness, and coping,
questions about psychostimulant
use, and wastewater samples
collected for 72-hour periods at
1-hour intervals at three time
points from four residence halls
comprising 476 undergraduate
students
Web-based survey about
cognitive enhancement drug use

Measures

115

Reference

Table 3 (Continued)
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assessment and inclusion of effect sizes was beyond the scope
of the present article.
The studies reviewed indicate that prescription stimulant misuse is a growing problem across adolescent and
adult populations. Estimates of lifetime prevalence range
from 7.1% to 29% among adults, 5.3% to 55% among college students, and 1.7% to 4.5% among adolescents.53,87–92
Although estimates of stimulant misuse prevalence appear
to be relatively low among general adolescent samples,
estimates of stimulant misuse among adolescents using other
substances (23%–31%) and among adolescents and adults
receiving treatment for ADHD (14%) are much higher.91–97
Estimates of lifetime stimulant misuse also appear to increase
as adolescents reach higher grade levels. For example, among
high school seniors, McCabe and West98 reported that nearly
10% admitted to using prescription stimulants nonmedically
at least once. Similarly, lifetime prevalence estimates in college have been shown to grow as students reach their final
years of school. Garnier-Dykstra et al56 reported that although
only 13.3% of first year students reported stimulant misuse,
by their fourth year 31% reported misuse.
In addition to college level, lifetime estimates of stimulant
misuse may vary according to several other variables. For
example, prevalence of stimulant misuse specifically for
cognitive enhancement was estimated to be ,2% in a sample
of preuniversity (students preparing to attend university)
and university students in Germany, but prevalence estimates of stimulant misuse for the purpose of weight loss
has been reported to be nearly 12%.99,100 Studies assessing
stimulant misuse among general samples of college students have reported rates between approximately 8% and
34%.54,101,102 Much higher estimates of stimulant misuse
have been reported among samples of college students with
ADHD (43%) or with prescriptions for stimulant medication
(45.2%). The highest estimates of prevalence of stimulant
misuse among college students (55%), however, have been
reported among a sample of fraternity members.90,103,104
Among medical students, lifetime prevalence estimates for engaging in prescription stimulant misuse have
ranged between 9%–10% and 18%.105–107 Moderate lifetime
prevalence estimates of stimulant misuse have also been
reported among undergraduate and graduate health care students (11%), dental and dental hygiene students (12.4%), and
general samples including both undergraduate and graduate
students (16.2%–17.5%).50,108–110
Compared with adolescents and college students, very
few studies have addressed prevalence estimates of stimulant misuse among adults aged $18 years outside of the
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university setting. Novak et al87 reported that 2% of the
4,297 adults sampled indicated that they had engaged in
nonmedical use of ADHD medications in the past year and
7.1% in their lifetime. Pilkinton and Cannatella88 reported
similar rates (7.1%) for lifetime prevalence estimates among
a sample of both adolescents and adults. However, estimates
of stimulant misuse prevalence among adults with prescriptions for stimulant medications have yielded much higher
rates (29%), similar to adolescent populations.89 Finally,
Lensing et al111 explored physician and adult patient agreement regarding prescription stimulant misuse and diversion
and found that ,1% of physicians suspected their patients
of diversion and ,2% of the adults themselves reported
diversion of prescription stimulants, yielding a high level
of agreement between the two.
Studies examining characteristics of students engaging in
stimulant misuse have yielded relatively consistent findings
regarding sex and race/ethnicity. Although multiple studies
reported that male students have indicated higher rates of
lifetime stimulant misuse than female students in university
settings, several studies have also failed to find differences
between males and females among college students and high
school senior students.44,52,98,99,101,105,107,110,112 These conflicting findings may be due to differences in measurement. For
example, although Franke et al99 reported sex differences
in lifetime prevalence of stimulant misuse for cognitive
enhancement, the researchers did not find differences across
males and females in past year or past month stimulant misuse. On the other hand, the vast majority of studies examining
racial and ethnic differences related to stimulant misuse have
reported that young adults, college students, and adults who
are white are more likely to misuse stimulants than students
of other races and ethnicities.49,53,88,91,98,99,101,113 Only one study
reported that there were no differences in ethnicity regarding prevalence of stimulant misuse; however, ,12% (n=37)
of the study’s sample included students of color, limiting
statistical power and thus conclusions regarding differences
in prevalence among ethnic differences.52
Interestingly, studies examining characteristics of adolescents who partake in nonmedical stimulant use indicate
that students without plans to attend college have been
shown to report a higher prevalence of stimulant misuse
than those who plan to attend college, and adolescents who
report prescription stimulant misuse may be less likely to
attend school.94,96 However, college students appear to be
particularly vulnerable to stimulant misuse, and members of
fraternities and sororities have reported higher rates of misuse
than students unaffiliated with Greek organizations.47,101,114
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One of the reviewed studies found that college students who
are upper classmen or live off-campus may be more likely to
engage in nonmedical stimulant use.90 Additional correlates
of stimulant misuse among college students have included
affiliation with a Jewish religion, perceiving stimulant use
as normative, and engaging in problematic weight loss
strategies.100,101,115 Weight loss, however, may not be unique to
college students, as adolescent prescription stimulant misusers have been found to be more likely to have an eating disorder than students who did not misuse stimulants.96 Finally,
all types of students (adolescents, adults, and medical)
performing worse academically appear to be more likely to
engage in nonmedical prescription stimulant use.56,99,101,105
Indeed, this review found that the most commonly reported
reasons university students take prescription stimulants are
related to academics, and studies suggest that during periods
of high academic stress, college students may be more likely
to use prescription stimulants, as indicated by self-report
measures and by measurements of stimulant levels in campus
wastewater samples.49,54,56,105,108,110,113,115
It is not surprising, then, that procrastination and difficulty
with time management have also been shown to relate to stimulant misuse among college students.115 Further, stimulant
misuse among college students has been shown to relate to
higher levels of hyperactivity, sensation seeking, depression,
internal restlessness, and psychological distress and lower
levels of premeditation.44,58,104,114,116 ADHD diagnoses and
symptoms may also relate to stimulant misuse. Adolescents,
college students, and adults diagnosed with ADHD have
reported higher levels of prescription stimulant misuse than
students without ADHD, and ADHD symptoms have been
shown to correlate with nonmedical use of prescription
stimulants.57,84,95,117 It is important to note, however, that studies suggest that the vast majority of individuals with ADHD
do not misuse or divert their stimulant medications.84
The studies included in the present review also indicate
that in addition to ADHD, diagnoses of conduct disorder
and SUD are associated with increased nonmedical prescription stimulant use and diversion in adolescents and
adults.84 Illicit drug use among adolescent and university
students is also associated with misuse of prescription
stimulants.52,56,90,91,93,98,101,103,104,107,115,118,119
Several studies in the current review assessed student
perspectives on prescription stimulant misuse, and findings
revealed that students’ opinions on the ethical implications of taking illicit prescription stimulant medications to
enhance academic outcomes are mixed. For example, Bossaer
et al108 reported that health care students were split between
considering stimulant misuse to be academically dishonest
242

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

and proffering unfair academic advantages. Similarly, half of
the medical students sampled by Emanuel et al107 perceived
stimulant misuse to be a problem, but 20% did not. Students
who report engaging in stimulant misuse, however, may feel
less conflicted regarding ethical implications. For example,
Judson and Langdon48 reported that compared with nonillicit
users, illicit users demonstrated fewer concerns regarding the
safety and ethics of using stimulant medication.
Whether or not students consider their decision to
engage in stimulant misuse to be ethical, students misusing
stimulants appear to expect positive outcomes.107,116 Indeed,
students who have reported taking stimulant medications
illicitly have endorsed feeling a reduction in fatigue and
improvement in cognition and memory after taking prescription stimulants.54 The present findings also indicate
that students who misuse tend to perceive the benefits as
outweighing the risks, despite the fact that little is known
about the physiological and cognitive effects of prescription
stimulant medications among populations without ADHD.49
Two of the reviewed studies suggest that individuals misusing stimulants may be more likely to take short-acting
agents than long-acting agents. Wilens et al84 and Bright,97
for example, reported that adolescents and adults were
more likely to misuse short-acting agents than long-acting
agents, suggesting that immediate-release agents have more
potential for abuse. Results were mixed regarding the most
commonly misused fast-acting stimulant, with Ritalin (MPH)
more likely to be misused than Adderall among adults, but
nearly 12% of college students reported misusing Adderall
compared with 8.5% misusing Ritalin.88,115

Discussion
Effectiveness of ADHD treatment options
Studies included in this review revealed that the medical use
of prescription stimulants is efficacious in reducing ADHD
symptoms and may improve cognitive and psychosocial
outcomes in individuals diagnosed with ADHD. Specifically,
research investigating LDX in comparison with placebo
consistently found LDX efficacious across 30, 50, and
70 mg/day. Two studies, however, found that higher doses
related to greater improvements in overall functioning.37,62
Most notably, the present findings support that LDX is effective for reducing ADHD symptomatology across different
ages.37,61,62 Among adults with ADHD, LDX was also found
to positively affect executive functions, quality of life, and
performance productivity.35,64,66 Additionally, LDX has been
found to be effective in reducing ADHD symptoms with
individuals with comorbid depression and SUD.63 Although
these results are encouraging, it is important to note that most
Psychology Research and Behavior Management 2014:7
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studies did report negative side effects from LDX, such as
decreased appetite, weight loss, and nasal congestion. More
severe side effects, however, including tachycardia, increased
blood pressure/hypertension, and anxiety, were reported
by ,5% of the included study samples, and no individuals
died while participating in these studies.
Similar to those investigating LDX, studies examining the
efficacy of MPH and D-AMP consistently found such treatment
options to be associated with fewer ADHD symptoms compared
with placebo. These positive effects were found among longacting and short-acting stimulant medications, and one study
reported similar effects for both males and females.78 Although
higher doses generally proved to be more effective at reducing
ADHD symptoms, low to moderate doses of stimulants may
also be effective at reducing ADHD symptomatology.70,74,76
Such treatment options examined in this review were associated with enhanced cognitive performance, executive functioning, and quality of life and fewer emotional symptoms.68,77,81
Although MPH and D-AMP have proved to be efficacious in
treating ADHD symptomatology, it is important to consider
their side effects that are similar to LDX: decreased appetite,
weight loss, headache, insomnia, abdominal pain, dizziness,
nervousness, emotional lability, and dry mouth. Although rare,
more severe side effects of these medications have included
psychosis, seizures, and cardiac events such as tachycardia,
hypertension, myocardial infarction, and sudden death.120
Overall, however, these results are consistent with the
child literature indicating that prostimulant and stimulant
medications, when used as prescribed, are a safe and efficacious treatment option for improving attention and decreasing hyperactivity and impulsivity symptoms.23,34–38,40–42 What
remains less clear, however, is whether these medications affect
academic and work-related outcomes of adolescents and adults
without ADHD. Although one study reported improvements
in measured cognition from MPH and another found that
students who misuse stimulant medication perceive positive
academic effects,54,68 none of the studies included in the present
review examined changes in quality of work or student grade
or productivity after taking stimulant medications. Given that
cognitive enhancement-related reasons are considered the
primary motivation for college students misusing prescription
stimulant medications, future research examining the effects of
prescription stimulants on direct measures of academic success
(eg, studying and concentration, grade performance, quality of
writing, and reading c omprehension) is warranted.
An additional area that warrants attention concerns the
efficacy of nonstimulant medication for the reduction of
ADHD symptoms and any potential effects for cognitive
enhancement. The present review was unable to identify any
Psychology Research and Behavior Management 2014:7
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studies examining nonstimulant efficacy among adults and
adolescents meeting the required eligibility criteria. Given
the lower abuse potential associated with nonstimulant
medication, use of these medications among populations
more susceptible to diversion and misuse may be prudent.32
Such a recommendation, however, is contingent on a demonstration of the efficacy of nonstimulants among adolescent
and adult populations most at risk for stimulant abuse.32
Finally, although prescription stimulant medication is
considered the front line of pharmacotherapy for ADHD
treatment in adolescents and adults, these drugs have significant diversion and misuse potential.43 In fact, the present
review revealed that the medical use of prescription stimulants is associated with increased stimulant misuse among
students with ADHD, with one study reporting misuse rates
of 62.8% among participants with a valid prescription.104

Stimulant misuse
Results from the present review indicate that a significant percentage of adolescents and adults are engaging in nonmedical
stimulant misuse, which is consistent with previous research
examining college students specifically.45 Results revealed
lifetime prevalence rates of stimulant misuse ranging from
1.7% to 55%, with reports varying across the population
being examined.90,91 A limitation of this body of literature is
the dearth of studies investigating the prevalence of prescription stimulant misuse among college students outside of the
US, which impedes cross-cultural comparisons regarding
prescription stimulant misuse.
Similar to previous studies examining the nonmedical use
of stimulants, the present review revealed that estimates vary
according to numerous variables. For example, one trend that
has emerged is that as individuals reach higher grade levels,
they misuse at greater rates.56,98 Although increased exposure
to prescription stimulants may be one reason students report
higher prevalence rates of stimulants as they increase in age,
these findings suggest that prescription stimulants may also be
misused more frequently as coursework becomes more challenging and academic success becomes more difficult to obtain.
Indeed, as indicated in this review, academic performance
has been reported as the primary motive for this behavior.
A critical finding, however, is that prescription stimulant misuse has been found to be negatively associated with academic
performance.44,90,101 For example, Arria et al121 reported that
college freshmen who used prescription stimulants nonmedically had poorer study skills (eg, skipped classes more often and
spent less time studying and more time socializing) and poorer
academic performance (GPA) in high school and college than
students who did not endorse stimulant misuse.51
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Despite the negative relationship between academic performance and stimulant misuse, most students who endorse
the nonmedical use of stimulants perceive them as effective
and helpful for enhancing their academic performance.49 For
example, Weyandt et al44 found that .20% of students in their
sample agreed or strongly agreed that the occasional nonmedical use of prescription stimulants is harmless. Additionally,
stimulant misusers may be less concerned about the safety
and ethical implications of stimulant misuse compared with
students who do not misuse stimulants.48 Findings suggest,
however, that general student populations are conflicted about
the ethical implications of stimulant misuse.
Although individuals without ADHD have endorsed
positive effects from misusing stimulant medication, to date
only one study has explored the effects of Adderall on college
students without ADHD, and this study, in general, did not
find enhancement of cognitive abilities, despite the students’
impression that it was improving their performance.122 Similar
performance-enhancing impressions have been made of MPH,
and have led to the popularity of its use among adolescents
and college students with and without ADHD.123 In addition,
the present review suggests that adolescents and adults are
more likely to misuse short-acting or immediate-release
agents compared with long-acting agents.84,97 Consistent
with previous studies, the present review suggests that students who are white, affiliated with a fraternity or sorority,
engaging in other illicit drugs, and male, are more likely to
misuse prescription stimulants.47,49,56,57,84,89,92,94,96,101,102,113,118,124
Although some of the studies reported no sex differences,
recently Weyandt et al45 reported on the effect sizes of sex
differences in studies examining stimulant misuse. Cohen’s
d effects ranged from 0.88 to 5.38, suggesting that males are
misusing at greater rates than females.109,110,125

Implications
Pharmacotherapy is the principal choice of treatment for
ADHD among children, adolescents, college students,
and adults.28,29 Because stimulants are the most frequently
prescribed drug for college students with ADHD, and most
college students with ADHD take prescription stimulants,
more double-blind, placebo-controlled studies examining
the effectiveness of these medications in college students
are warranted.22 It is important to note, however, that there
is recent evidence that prostimulants may also be effective at
improving symptoms in individuals with ADHD.28
The present review provides evidence that college
students with ADHD and those with a stimulant prescription are taking part in greater levels of stimulant misuse
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compared with those without the disorder.103,104 Although
individuals with ADHD may greatly benefit from stimulant
medication, these prescription medications have significant
abuse potential when they are not used as prescribed.43 All
prescription stimulants that are used to treat ADHD are
controlled substances; however, abuse liability varies based
on the delivery system in which the medication activates.126
For example, Svetlov et al123 reported that although MPH
and AMPH have similar psychopharmacological effects,
they do have different neurochemical mechanisms of action.
Such differences are essential to consider, as MPH appears
to have less rewarding abilities, lowering its chances of
dependence, especially when taken as prescribed. A second
example includes the requirement of enzymatic hydrolysis
for LDX before its therapeutic effects are achieved, which
results in a slow increase of D-AMP levels, potentially
lowering its use for diversion or misuse.37,127 Indeed, recent
research has examined the effects of LDX in a group of
stimulant abusers who did not have ADHD, and found
that intravenous doses of LDX had greater abuse-related
disliking compared with placebo.127 Specifically, Jasinski
and Krishnan127 administered 100 mg of LDX and 40 mg
of D-AMP to individuals, also reporting that intravenous
doses of D-AMP have significantly more abuse-related liking
effects compared with placebo. Additionally, because of its
chemical properties, LDX cannot be ground or dissolved
into a short-acting stimulant, which has been the stimulant
of choice for stimulant misusers. Given the demonstrated
effects of LDX on improving ADHD symptomology, as well
as executive function, and its demonstrated greater abuserelated disliking, LDX may be the ADHD medication of
choice for college students with ADHD who are at risk for
stimulant misuse.37,127 LDX may also be a good choice for
prescribers working with the college student population to
help prevent stimulant diversion among valid prescription
holders and misuse among college students without ADHD.
Results of this review also suggest that health care providers should inform their patients of the health and legal risks
associated with the misuse of prescription medications, and
monitor the use of these medications on a frequent basis.
Lastly, health care providers involved in prescribing
ADHD-related medications should be thoroughly trained in
the proper assessment, diagnosis, and treatment of ADHD to
ensure diagnostic accuracy and treatment effectiveness.
In addition to educating prescribers about the rates of
misuse and diversion, as well as the variables associated with
stimulant misuse, it is critical that prevention and intervention
efforts be made amongst health care providers and educators
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at the middle school, high school, and higher education levels.
Further efforts should target particularly higher-risk college
populations such as fraternities and sororities. Information
regarding the potential side effects of stimulant medications
taken at varying doses and by different methods (eg, snorting
or injecting), in addition to side effects resulting from the ingestion of medication as prescribed, should be made available to
students in particular. Students should also be informed of the
dangers of coingestion of prescription stimulants with other
substances (eg, alcohol and cocaine), and particular emphasis
should be placed on maintaining security of their medication
(eg, lockboxes). Students who are misusing prescription stimulants without medical guidance are placing themselves at health
and psychological risk, in addition to legal consequences for
buying, selling, and diverting their medications.120
The inclusion of a psychoeducational component that
focuses on inaccurate perceptions of safety surrounding
nonmedical prescription stimulant use would be beneficial
to intervention as well. Students who are at risk for stimulant
misuse with academic problems can be provided with various support, such as tutoring and structured environments
for studying and work completion. This additional support may encourage a school culture of clear expectations,
educational support, and effective study habits, rather than
competitiveness. For individuals who have been misusing
stimulants or are inclined to misuse, it is imperative to
discuss the motivating factors and determine any possibly
undiscovered psychological, social, and/or emotional problems related to misuse or the desire to misuse. By pinpointing
and addressing the core cause of stimulant use, students can
be provided with the resources that will directly provide them
with benefits and alternative methods to meet their specific
needs. Thus, students should be educated about the potential
side effects and risks associated with prescription stimulant
misuse, as well as encouraged to access campus resources
for academic and psychological support.45,47

Conclusion
Results from the present review support that both stimulant and prostimulant medications (including LDX, MPH,
AMPH, and MAS), when used as prescribed, are safe and
effective options for reducing ADHD symptoms in adolescents and adults with ADHD. Preliminary studies also suggest that prescription stimulants may improve psychosocial
outcomes (eg, quality of life, self-concept, and obsessive–
compulsive symptoms) for those with ADHD. Research
explicitly examining effects of prescription stimulants on
academic and cognitive functioning in students without
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ADHD is sorely limited, yet the current review revealed that
alarmingly high percentages of adolescents and adults are
engaging in nonmedical prescription stimulant use primarily for cognitive enhancement. Results of the present review
also revealed a higher rate of prescription stimulant misuse
among individuals with ADHD compared with individuals
without the disorder, and that short-acting agents are more
likely to be misused than long-acting agents. These findings
emphasize the need for additional research concerning the
misuse of prescription stimulants and have direct implications
for prevention and intervention efforts to reduce prescription
stimulant misuse among adolescents and young adults.
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